The global blood screening market was valued at USD 3.40 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 11.9% from 2025 to 2030. This growth is primarily driven by an increasing number of blood donations worldwide, which requires stringent screening protocols to prevent the transmission of infections through transfusions. Technological advancements, particularly in automation and molecular diagnostic platforms, have improved both the efficiency and accuracy of blood screening processes. Additionally, the rising prevalence of infectious diseases and government-backed initiatives promoting blood safety contribute to this market expansion. There is also growing public awareness about the importance of safe blood transfusions, which further supports market growth.
Blood screening is an essential medical process in which blood samples are analyzed to identify health conditions and potential abnormalities. This diagnostic tool provides crucial insights into a person’s health status, helping detect, prevent, and manage various diseases at an early stage. Blood screening involves assessing blood cell counts, identifying infectious agents like viruses and bacteria, and measuring specific chemical levels, such as cholesterol and glucose. The value of blood screening lies in its ability to allow healthcare providers to detect health issues before symptoms become evident, making it a critical tool for diagnosing conditions such as anemia, diabetes, infections, and cardiovascular diseases.
Gather more insights about the market drivers, restrains and growth of the Blood Screening Market
Ongoing technological innovations have significantly enhanced the precision and efficiency of screening techniques. Moreover, increased awareness about the benefits of early disease detection has led to a greater emphasis on preventive healthcare practices. The aging global population also contributes to demand growth, as the prevalence of age-related conditions that require regular blood screening rises.
In addition, rising global healthcare expenditures support the adoption of advanced technologies and services within blood screening, as healthcare providers seek to implement the latest and most effective diagnostic tools. These factors collectively fuel the growth and development of the blood screening market, highlighting its role in proactive healthcare strategies aimed at improving patient outcomes and public health.
Technology Segmentation Insights:
Nucleic Acid Amplification Tests (NAT) led the blood screening market, capturing a revenue share of 41.2% in 2024. The high demand for NAT is attributed to the increasing prevalence of infectious diseases, such as HIV and hepatitis, which require accurate and rapid testing that NAT provides. NAT tests are known for their high sensitivity and specificity, enabling them to detect even low levels of viral loads that traditional methods may not identify. The rising demand for early disease diagnosis and monitoring further propels the adoption of NAT. Technological improvements in amplification techniques also enhance the speed and efficiency of these tests, making them more suitable for use in clinical settings.
Next Generation Sequencing (NGS) is expected to grow at a CAGR of 16.5% over the forecast period. This technology has transformed genomic analysis by dramatically lowering sequencing costs while increasing accuracy. NGS allows for comprehensive profiling of genetic mutations, which is essential for personalized medicine and targeted therapies. Additionally, NGS’s ability to process multiple samples simultaneously increases laboratory throughput, making it an appealing choice for healthcare providers. The continuous advancements in NGS technologies ensure their relevance in applications such as early disease detection and monitoring, which supports market growth.
Overall, the development and adoption of advanced blood screening technologies like NAT and NGS drive the market’s expansion, underscoring their importance in delivering accurate, timely, and personalized healthcare solutions.
Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian